Clinical trial
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
NCT01065935 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
- Lead sponsor
- Alnylam Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2010
- Completion date
- May 31, 2012
- Enrollment
- 87 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.